VRAX
Virax Biolabs Group Ltd - Class A (VRAX)
Healthcare • NASDAQ • $0.17+26.67%
- Symbol
- VRAX
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $0.17
- Daily Change
- +26.67%
- Market Cap
- $1.27M
- Trailing P/E
- N/A
- Forward P/E
- -0.71
- 52W High
- $1.20
- 52W Low
- $0.10
- Analyst Target
- $1.00
- Dividend Yield
- N/A
- Beta
- 1.05
Virax Biolabs Group Limited, a biotechnology company, distributes diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of T cell in Vitro Diagnostics. The company offers various in-vitro diagnostics test kits comprising respiratory, pregnancy and fertility, infectious diseases, sti, drugs of abuse, oncology, cardiac, women's health, other test kits under the ViraxClear brands; and rapid and molecular tests for small animal veterinary diagnostics under the ViraxVet brand. It also provides ViraxImmune, a T cell In vitro diagnostic device and wellness mobile application; and service, such as antibody engineering, custom peptides, protein sequencing, vaccine efficacy testing, immunology lab services, kits and reagents. In addition, …
Company websiteResearch VRAX on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.